Summary

Prostate specific antigen (PSA) is an exceptional biomarker for prostate cancer. While there has been a significant decrease in prostate cancer mortality since the introduction of PSA screening, the benefit of screening can be diminished by the loss of quality of life (QoL) stemming from both the diagnosis itself and the adverse effects of treatment. This article quantifies the effects of screening strategies on prostate cancer mortality and QoL.